IKE Tech Files First-Ever PMTA for Standalone Interoperable Blockchain-based Age-Gating System at Point of Use - Marking a New Chapter in Youth Vaping Prevention
This marks the first ever complete PMTA submission for a standalone, scalable age-gating component that provides real-time continuous age verification at the point-of-use for electronic nicotine delivery systems (ENDS). The IKE System is designed for universal integration across all ENDS devices, utilizing unique blockchain-based tokenization technology to further ensure user privacy and security.
According to a multi-center Human Factors Validation Study submitted as part of the PMTA, the IKE system proved to be 100% effective in preventing device activation for anyone under the age of 21. The company has formally requested expedited review of its application, emphasizing the system's potential to enhance public health.
'This is a major milestone for IKE Tech and the ENDS category', commented John Patterson, President of IKE Tech. 'We're not just building technology. We're paving a new regulatory framework that gives the FDA and manufacturers powerful tools to safeguard public health and ensure adult-only access to vaping products. With proven, scalable age-gating technology built into ENDS devices, the sector now has a real opportunity to eliminate underage vaping for good'.
One chip, every device: unlocking new era of vaping
IKE Tech adopted a rigorous software development lifecycle, following consultation with the FDA. The IKE platform offers a seamless identity and age verification experience via a single, user-friendly mobile app available on iOS and Android. By leveraging blockchain technology, it securely validates user's identity and age through integrated identity verification (IDV) partners, anchoring credentials to a tokenization system without storing sensitive data on user's device, nor on IKE's system, to ensure complete user privacy and security.
Unlike existing solutions that allow permanent access after a single verification, IKE's system requires continuous verification to maintain device access. Human Factors Validation study showed 91% of users (aged 18 – 67) rated the app as 'Extremely Easy' or 'Very Easy' to use - with a user error rate of less than 0.8% - proving its appeal to the wider market.
'This is a pivotal moment from a regulatory perspective,' said Kevin Burd, CEO of Chemular. By embedding robust age verification at the point of use, the IKE technology enables manufacturers and regulators to confidently allow access to a broader range of products for verified adults. This approach opens the doors for responsible flavor pathways, empowering adult consumers with more choice, while maintaining the highest levels of youth protection.'
Building Smarter and Better ENDS
IKE Tech is dedicated to building a better, more secure future for all. To meet the evolving needs of manufacturers, the company is planning to continue integrating advanced features like counterfeit protection, geofencing, targeted messaging, and real-time data access to its systems.
These innovations are designed to address underage vaping and combat the illicit market, ensuring that only products that FDA has determined are Appropriate for the Protection of Public Health (APPH) are available to adult users.
To learn more about IKE Tech, visit www.iketech.com.
Notes to Editors:
Human Factors Study Design and Key Results
Conducted with 102 participants (51% male, 49% female, aged 18–67 across race/ethnic demographics), the study simulated real-world use of the IKE system. Participants downloaded the app, verified their age, paired with a test device and interacted with BLE-based access controls including biometric reactivation.
Key performance highlights:
Devices could only be reactivated with biometric authentication. Demographic data (age, race/ethnicity, gender) was accurately verified in all cases. The results confirm the IKE System's ability to reduce user error, prevent underage access, and provide a user-friendly experience for adults.
About IKE Tech
IKE Tech LLC ('IKE Tech') is pioneering real-time age and identity verification at the point of use, helping to safeguard access to age-restricted products.
A leading innovator at the intersection of Internet of Things (IoT), identity verification (IDV), and tokenization technology, IKE Tech has developed an industry-first, scalable age-gating component that provides continuous, real-time verification for electronic nicotine delivery systems (ENDS) and other restricted consumer products.
IKE Tech's interoperable Bluetooth Low Energy (BLE) System-on-a-Chip, powered by a user-friendly mobile app available on iOS and Android, integrates seamlessly into ENDS devices, giving manufacturers and regulators a flexible, future-proofed solution to combat underage vaping and illicit markets. By setting the new standard for responsible, adult-only access, IKE Tech is helping eliminate youth vaping for good.
View original content: https://www.prnewswire.com/news-releases/ike-tech-files-first-ever-pmta-for-standalone-interoperable-blockchain-based-age-gating-system-at-point-of-use---marking-a-new-chapter-in-youth-vaping-prevention-302443438.html
SOURCE IKE Tech LLC
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Biogen Inc. (BIIB): A Bull Case Theory
We came across a bullish thesis on Biogen Inc. on r/Valueinvesting subreddit by U/Lobyous. In this article, we will summarize the bulls' thesis on BIIB. Biogen Inc.'s share was trading at $131.52 as of July 25th. BIIB's trailing and forward P/E were 13.00 and 8.85 respectively according to Yahoo Finance. A scientist in a lab, researching for a breakthrough treatment for Alzheimer's disease, diabetes nephropathy, asthma, COPD, NASH, and Type 1 Diabetes. Biogen (BIIB) remains deeply unloved by the market, largely due to its missteps with the FDA on Alzheimer's drug Aduhelm, yet it continues to generate substantial and durable cash flows from its existing portfolio, with visibility for at least the next 5–10 years. The company's legacy blockbusters Tecfidera and Tysabri face erosion from generics, but overall revenue has proven more resilient than expected, while growth drivers like Leqembi are set to gain traction, potentially contributing over $5 billion in revenue over the next four years. Management has sought to bolster its relatively thin pipeline through acquisitions, most notably Reata Pharmaceuticals and its drug Skyclarys, and now has six Phase III candidates, with at least two—Tofersen and Felzartamab—showing strong prospects to become blockbusters by 2030. Despite recent challenges, Biogen delivered $2.72 billion in 2024 free cash flow, equating to a compelling 16% yield at the current market cap, with even a conservative forecast—assuming a 3% annual revenue decline through 2030 and excluding any pipeline or acquisition upside—suggesting a 10% margin of safety. Broader market conditions may also work in Biogen's favor, as the healthcare sector trades at historically low valuations, and a shift in sentiment could re-rate the stock. Near-term catalysts include stronger Leqembi uptake and one to two solid quarters that could draw institutional investors back. With shares trading in the $115–$130 range, Biogen offers an asymmetric risk/reward profile, and at sub-$115 levels appears highly attractive given its durable cash flows, undervalued pipeline, and potential for sector-wide recovery. Previously, we covered a bullish thesis on Gilead Sciences, Inc. (GILD) by Disruptive Analytics in February 2025, which highlighted resilience in profitability despite headwinds from the Inflation Reduction Act, currency impacts, and declining COVID sales. The company's stock price has appreciated by approximately 11.64% since our coverage, as the thesis played out. The thesis still stands as Gilead's fundamentals remain intact. u/Lobyous shares a similar view but emphasizes Biogen's undervaluation and catalysts from Leqembi. Biogen Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 52 hedge fund portfolios held BIIB at the end of the first quarter which was 52 in the previous quarter. While we acknowledge the potential of BIIB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. Sign in to access your portfolio
Yahoo
3 hours ago
- Yahoo
Brachytherapy Devices Market is Growing at CAGR of 6.7% During 2025 -2031 to Reach US$534.20 Million
NEW YORK, Aug 4, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the Brachytherapy Devices Market is witnessing significant growth due to the rising incidence of cancer worldwide and technological advancements in brachytherapy devices. The Brachytherapy Devices Market value is expected to reach US$534.20 million by 2031 from US$343.57 million in 2024; the market is anticipated to register a CAGR of 6.7% during 2025–2031. The market growth is attributed to the rising incidence of cancer worldwide, the aging population, and the technological advancements in brachytherapy devices. The Brachytherapy Devices Market analysis focuses on advancements such as MRI-compatible applicators and real-time imaging integration that play a vital role in the market growth. The report runs an in-depth analysis of market trends, key players, and future opportunities. Check valuable insights in the Brachytherapy Devices Market report. You can easily get a sample PDF of the report - Overview of Brachytherapy Devices Market Report Findings Rising Incidence of Cancer Worldwide:As per the GLOBOCAN 2020 report, more than 28.4 million new cancer cases are expected to be reported by 2040. An aging population, lack of physical activity, exposure to pollutants in the environment, and alterations in diet lead to increased rates of an internal radiation treatment, is ideal for the treatment of prostate, cervical, breast, and skin cancers. It allows for the radiation to be targeted directly to the tumor and avoid the surrounding healthy tissues, with reduced side effects and improved recovery times. Thus, brachytherapy is becoming increasingly popular among oncologists and cancer remains among the major causes of mortality globally, demand for effective, low-invasive, and affordable treatment procedures is rising. Brachytherapy is meeting this demand, particularly in facilities where it might not be possible to access highly advanced external radiation facilities. Thus, the increasing burden of cancers worldwide propels the market growth. Technological Advancements in Brachytherapy Devices:Advances in the area are improving the accuracy, safety, and effectiveness of treatments, making brachytherapy a progressively appealing choice for cancer technological advancements include the creation of high-dose rate (HDR) and low-dose rate (LDR) machines, which provide more accurate radiation delivery. HDR machines provide for administering higher doses of radiation in shorter times, making treatment faster and more convenient for patients. MRI-compatible applicators and integration of sophisticated imaging are providing better tumor localization and online monitoring of treatment. These advances allow clinicians to target tumors effectively with less exposure to healthy tissues in the proximity. The robot-assisted platforms provide higher accuracy and precision, particularly in challenging anatomical areas. In addition, miniaturization and mobility of brachytherapy equipment are facilitating treatments, especially in developing advances in technology are making brachytherapy more effective and safer but and increasing its uses in treating a broader spectrum of cancers. Consequently, the greater uptake of these machines is contributing to their adoption and setting the limits of cancer treatment even higher. Geographical Insights: In 2024, North America led the market with a substantial revenue share, followed by Europe and Asia Pacific. Asia Pacific is expected to register the highest CAGR during the forecast period. Stay Updated on Brachytherapy Devices Market Trends: Brachytherapy Devices Market Segmentation Based on product, the Brachytherapy Devices Market is segmented into seeds, brachytherapy afterloaders and applicators, and electronic brachytherapy. The brachytherapy afterloaders segment held the largest market share in 2024. In terms of type, the Brachytherapy Devices Market is categorized into high-dose rate brachytherapy implant and low-dose rate brachytherapy implant. The low-dose rate brachytherapy implant segment dominated the market in 2024. By application, the Brachytherapy Devices Market is segmented into breast cancer, cervical cancer, prostate cancer, lung cancer, and others. The prostate cancer segment dominated the market in 2024. Per end user, the Brachytherapy Devices Market is divided into hospitals and specialty clinics, ambulatory surgical centers, and others. The hospitals and specialty clinics segment dominated the market in 2024. The Brachytherapy Devices Market is segmented into five major regions: North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. Competitive Strategy and Development Key players: Elekta, Varian Medical Systems, Inc., BEBIG Medical, Theragenics Corporation, IsoAid, Siemens Healthineers AG, BXTA, BD, and Eckert and Ziegler are among the major companies operating in the Brachytherapy Devices Market. Trending topics: Advancements in Imaging Technologies, Government Initiatives and Cancer Treatment Programs, Technological Advancements in Brachytherapy Devices, Integration of Artificial Intelligence (AI) and Robotics in brachytherapy, etc. Headlines on Brachytherapy Devices Market Artemis Hospital Announces the Launch of Brachytherapy Services, Expanding Advanced Cancer Care Papua New Guinea Resumes Radiotherapy, Starts Brachytherapy Services with IAEA Support BEBIG Medical Launches SagiNova Brachytherapy System at Father Muller Hospital as a Part of New Healthcare Wing Medanta Patents MAOLO Brachytherapy Device For Advanced Cervical Cancer Treatment Elekta Expands Brachytherapy Portfolio With Acquisition of iCad Inc.'s Xoft Business CivaTech Oncology Receives FDA Approval for CivaSheet Brachytherapy Device Get Premium Copy of Brachytherapy Devices Market Size and Growth Report by 2031 at: Conclusion The growth of the Brachytherapy Devices Market is fueled by the increasing prevalence of cancer, advances in technology, and soaring demand for minimally invasive treatment options. The high-dose rate (HDR) systems, MRI-compatible applicators, and robotic-assisted devices are increasing the accuracy of treatment and speeding up patient recovery. Further, there is a growing demand for affordable and patient-centric therapies, particularly in areas that have poor access to conventional cancer therapy. With increasing uses in prostate, breast, and cervical cancers, the demand for brachytherapy is surging, with better results and accessibility in cancer therapy. The report from The Insight Partners provides several stakeholders—including manufacturers of seeds, brachytherapy afterloaders and applicators, and electronic brachytherapy devices—with valuable insights to navigate this evolving market landscape and unlock new opportunities. Trending Related Reports: Brachytherapy After Loaders Market Strategies, Top Players, Growth Opportunities, Analysis and Forecast by 2031 Cancer Therapy Market Scope, Share, and Size by 2031 Pancreatic Cancer Therapy Market SWOT Analysis by 2031 Lung Cancer Therapy Market Research Report by 2030 Cancer Biopsies Market Trends, Share, and Growth – 2031 Cervical Cancer Diagnostics and Therapeutics Market Size 2031 Kidney Cancer Therapeutics And Diagnostics Market Size 2031 Cancer Biopsies Market Trends, Share, and Growth - 2031 Thyroid Cancer Diagnostics Market Growth and Share by 2031 About Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials. Contact Us:If you have any queries about this report or if you would like further information, please get in touch with us:Contact Person: Ankit MathurE-mail: +1-646-491-9876 Logo: View original content: SOURCE The Insight Partners Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Associated Press
4 hours ago
- Associated Press
Levi & Korsinsky Reminds Capricor Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 15, 2025
NEW YORK - August 4, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Capricor investors who were adversely affected by alleged securities fraud between October 9, 2024 and July 10, 2025. Follow the link below to get more information and be contacted by a member of our team: CAPR investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: According to the complaint, defendants provided investors with material information concerning Capricor's lead cell therapy candidate drug deramiocel for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Defendants' statements included, among other things, Capricor's ability to obtain a Biologics License Application (BLA) for deramiocel from the U.S. Food and Drug Administration (FDA). Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning its four-year safety and efficacy data from its Phase 2 HOPE-2 trial study of deramiocel. On July 11, 2025, Capricor issued a press release announcing it received a Complete Response Letter (CRL) from the FDA denying the BLA specifically citing it did not meet the statutory requirement for substantial evidence of effectiveness and the need for additional clinical data. Further, the CRL referenced outstanding items in the Chemistry, Manufacturing, and Controls section of the application. Following this news, the price of Capricor stock declined from $11.40 per share on July 10, 2025 to $7.64 per share on July 11, 2025. WHAT'S NEXT? If you suffered a loss in Capricor during the relevant time frame, you have until September 15, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To learn more about this case, subscribe to the Bulls & Betrayals podcast, which features a dedicated episode unpacking the allegations against Capricor. Listen now and find out if you are eligible to join the lawsuit. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. Ed Korsinsky, Esq. 33 Whitehall Street, 17th Floor New York, NY 10004 [email protected] Tel: (212) 363-7500 Fax: (212) 363-7171 View the original release on
